Introduction {#s1}
============

Atherosclerosis (AS) is a common, multifactorial disease that causes significant morbidity and mortality worldwide [@pone.0086480-World1]. Its exact mechanisms are still unclear. Multiple environmental and lifestyle factors may significantly contribute to the AS risk, such as climate, diet, age, and economic status. The risk of developing AS tends to run in families, which suggests the genetic factors play a crucial role in the development of AS. Until recently, many studies have focused on this field, and ATP-binding cassette transporter 1 (ABCA1) gene has been extensively studied [@pone.0086480-Clee1]--[@pone.0086480-Liu1].

It is widely accepted that a low level of plasma high-density lipoprotein cholesterol (HDL-C) is a major risk factor for atherosclerotic diseases in the general population [@pone.0086480-Stampfer1]. ABCA1, a member of the ATP-binding cassette family,could promote the HDL formation and the cholesterol efflux, thus impacting the development of AS [@pone.0086480-Nebel1]. Previous studies have reported that the mutations in ABCA1 are responsible for two forms of heritable HDL disorders, namely Tangier disease (Homozygosity) and familial hypoalphalipoproteinemia (heterozygosity) [@pone.0086480-BrooksWilson1], [@pone.0086480-Bodzioch1]. Given the crucial role of ABCA1 in the HDL formation and the cholesterol efflux, the mutations in ABCA1 may also play a significant role in the development of atherosclerotic diseases. Recently, a number of molecular epidemiological studies have been done to evaluate the associations between the ABCA1 gene polymorphisms (such as R219K, M883I, C69T, V825I, R1587K, V771M and −565C/T) and the risk of atherosclerotic diseases [@pone.0086480-Clee1]--[@pone.0086480-Liu1]. However, results of different studies have been inconsistent, possibly due to small sample sizes in the individual studies. In 2011, Ma et al. performed a meta-analysis to evaluate the association between the ABCA1 R219K polymorphism and coronary artery disease (CAD), and demonstrated that the ABCA1 R219K polymorphism was a protective role for CAD both in Asians and Caucasians [@pone.0086480-Ma1]. In 2012, Li et al. also conducted a meta-analysis to evaluate the association of this variant with CAD [@pone.0086480-Li4]. However, they just found the ABCA1 R219K polymorphism was a protective factor in Asians, but not in Caucasians. Considering the above two meta-analyses only focused on the association of ABCA1 R219K polymorphism with the single atherosclerotic disease, we therefore performed this meta-analysis of all the studies available now to derive a more precise estimation of the associations between the ABCA1 R219K and M883I polymorphisms and overall AS risk.

Materials and Methods {#s2}
=====================

Literature Search {#s2a}
-----------------

This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) criteria and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines [@pone.0086480-Moher1], [@pone.0086480-Stroup1]. Eligible literatures published before the end of November 15, 2013 were identified by the search of PubMed, Embase, Web of Science, Medline, Cochrane database, Clinicaltrials.gov, Current Controlled Trials, Chinese Clinical Trial Registry, CBMdisc, CNKI, Google Scholar and Baidu Library using combinations of the following keywords: ("ATP-binding cassette transporter A1" OR "ATP-binding cassette sub-family A member-1" OR "ABCA1") AND ("polymorphism" OR "mutation" OR "variant" OR "variation" OR "genotype") AND ("coronary artery disease" OR "CAD" OR "coronary heart disease" OR "CHD" OR "myocardial infarction" OR "MI" OR "ischemic cardiovascular disease" OR "ischemic cardiovascular events" OR "ischemic stroke" OR "IS" OR "cerebrovascular disease" OR "ischemic cerebrovascular events" OR "cerebral infarction" OR "cerebral ischemia" OR "brain infarction" OR "carotid artery stenosis" OR "CAAD" OR "transient ischemic attack" OR "TIA" OR "peripheral Arterial Disease" OR "PAD" OR "peripheral artery occlusive disease" OR "PAOD" OR "renal artery stenosis" OR "RAS" OR "retinal artery occlusion" OR "RAO" OR "aortic aneurysm" OR "atherosclerosis"). In addition, all references cited were reviewed to identify additional studies. Two reviewers (Yin YW and Zhang LL) searched the above databases independently. Decisions were compared and disagreements about study selection were resolved by involving a third reviewer (Li JC). The search was limited to English and Chinese language papers. There was no restriction on time period, sample size, or population.

Inclusion and Exclusion Criteria {#s2b}
--------------------------------

To be included in the present meta-analysis, the studies had to comply with the following major criteria: (1) case-control or cohort studies evaluating the associations between the ABCA1 R219K and M883I polymorphisms and AS risk; (2) published studies with full text articles; (3) Diagnosises of atherosclerotic diseases were made according to the internationally recognized diagnostic criterion. The diagnosis of ischemic heart disease (CAD and MI) is accorded with the result of coronary angiography, criteria of World Health Organization (WHO), criteria of European Society of Cardiology (ESC), or criteria of American College of Cardiology/American Heart Association (ACC/AHA), and the diagnosis of IS is accorded with result of computed tomography (CT) or magnetic resonance imaging (MRI); (4) sufficient published data for calculating odds ratios (ORs) with their 95% confidence intervals (CIs).

Studies were excluded if they were: (1) Review; (2) Not conducted in humans; (3) Duplicate studies.

Data Extraction {#s2c}
---------------

Data, including name of the first author, year of publication, study population (country, ethnicity), study type (case-control and cohort study), type of atherosclerotic disease, source of controls (population-based studies and hospital-based studies), sample size (total numbers of cases and controls), and number of genotypes in cases and controls, were extracted from each study by two reviewers independently (Yin YW and Zhang LL) according to the pre-specified inclusion criteria. Decisions were compared and disagreements about study selection were resolved by consensus or by involving a third reviewer (Li JC).

Quality Assessment for Individual Studies {#s2d}
-----------------------------------------

The quality of the individual studies was evaluated and scored by two reviewers independently based on the Newcastle-Ottawa Scale (NOS) [@pone.0086480-Wells1]. Each study was assessed based on three broad perspectives: selection, comparability, and exposure, and each satisfactory answer received one point. The NOS ranges between zero (none of the quality criterion was met) up to nine stars (all the quality criteria were met), and the high-quality study was considered as the one with a score equal to or higher than seven. The third reviewer (Li BH) examined the results, and a consensus was reached.

GRADE Quality Assessment {#s2e}
------------------------

GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach was adopted to grade quality of evidence for each association [@pone.0086480-Guyatt1]. The GRADE system included: level of evidence: (1) high quality; we are very confident that the true effect lies close to that of the estimate of the effect, (2) moderate quality; we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different, (3) low quality; our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect and (4) very low quality; we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. Two reviewers (Wang JZ and Zhang MJ) assessed quality independently and solved disagreement by discussion.

Statistical Analysis {#s2f}
--------------------

For the controls of each study, Hardy-Weinberg equilibrium (HWE) was assessed using the chi-square test (*P*\<0.05 was considered significant deviation from HWE). The strength of associations between the ABCA1 R219K and M883I polymorphisms and AS risk were assessed by ORs with 95% CIs. The pooled ORs were performed for allelic model (K allele vs. R allele for R219K; I allele vs. M allele for M883I), additive model (K/K vs. R/R for R219K; I/I vs. M/M for M883I), recessive model (K/K vs. R/K+R/R for R219K; I/I vs. M/I+M/M for M883I), and dominant model (K/K+R/K vs. R/R for R219K; I/I+M/I vs. M/M for M883I). Heterogeneity across individual studies was calculated using the Cochran's Q statistic and the I^2^ statistic (*P*\<0.10 and I^2^\>50% indicated evidence of heterogeneity) [@pone.0086480-Higgins1], [@pone.0086480-Berkey1]. Meta-regression was performed subsequently to explore the heterogeneity sources. The pooled OR was estimated by the random-effects model. Subgroup analyses were performed based on ethnicity (Caucasians and Asians), atherosclerotic diseases (CAD and IS), source of controls (population-based studies and hospital-based studies) and study type (case-control and cohort study). Sensitivity analyses were performed based on HWE (studies without HWE were excluded), NOS score (studies with score ≤6 were excluded) and article type (master theses were excluded). Begg's funnel plot and Egger's regression test were conducted to identify possible publication bias in the current meta-analysis (*P*\<0.05 was considered representative of statistically significant publication bias) [@pone.0086480-Egger1]. In addition, fail-safe number (Nfs ~0.05~) was calculated to explore the extent to which the "file drawer problem" may have affected study results. All statistical analyses were done with Stata software (Version 11; StataCorp LP, College Station, TX).

Results {#s3}
=======

Characteristics of the Studies {#s3a}
------------------------------

The present study met the PRISMA statements and MOOSE guidelines ([Checklist S1](#pone.0086480.s011){ref-type="supplementary-material"}, [Table S1](#pone.0086480.s007){ref-type="supplementary-material"} and [Fig. 1](#pone-0086480-g001){ref-type="fig"}). A total of 1184 articles were identified after searching. After careful review, 47 articles involving 58 studies (42 studies for R219K polymorphism and 16 studies for M883I polymorphism) met the inclusion criteria and were selected in this meta-analysis [@pone.0086480-Clee1]--[@pone.0086480-Liu1]. For the ABCA1 R219K polymorphism, 12551 AS cases and 19548 controls were included to assess the association between the variant and AS risk [@pone.0086480-Clee1]--[@pone.0086480-Xia1]. For the ABCA1 M883I polymorphism, 4224 AS cases and 3462 controls were identified to assess the association of the variant with AS risk [@pone.0086480-Sun1], [@pone.0086480-Li1], [@pone.0086480-Martn1], [@pone.0086480-Andrikovics1], [@pone.0086480-FrikkeSchmidt1], [@pone.0086480-PorchayBaldrelli1], [@pone.0086480-Tan1]--[@pone.0086480-Liu1]. Main characteristics of the included studies were listed in [Table 1](#pone-0086480-t001){ref-type="table"} and [Table 2](#pone-0086480-t002){ref-type="table"}. The most commonly atherosclerotic disease included in the present meta-analysis was CAD. In addition, there were nine studies involving IS, five studies involving MI, and one study involving IS and carotid artery atherosclerosis (CAA). There were 40 studies of Asians, 18 studies of Caucasians, and one study of mixed population. Four studies did not follow the HWE [@pone.0086480-Chang1], [@pone.0086480-Wang4], [@pone.0086480-Tan1], [@pone.0086480-Zhang3] and two studies have insufficient data for calculation of the HWE [@pone.0086480-Martn1], [@pone.0086480-FrikkeSchmidt1]. The NOS results showed that the average scores were 6.9 and 6.8, respectively. In addition, the results of GRADE were shown in [Table S2](#pone.0086480.s008){ref-type="supplementary-material"}.
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###### Characteristics of studies included in this meta-analysis.

![](pone.0086480.t001){#pone-0086480-t001-1}

                                                                Study             Source of   Sample size                HWE                                                  
  ------- -------------------- ------ ----------- ------------ ------- --------- ----------- ------------- ---------- ---------- --------- ------------ ---------- ---------- ---
                  Clee          2001    Canada     Caucasians    CS       CAD        HB         432/358     248/176    170/160     14/22     666/512     198/204    Y(0.067)   6
               Brousseau        2001      USA      Caucasians    CCS      CAD        PB        1014/1013    454/543    484/402     76/68    1392/1488    636/538    Y(0.580)   7
                Cenarro         2003     Spain     Caucasians    CCS      CAD        HB         216/158      123/72     78/71      15/15     324/215     108/101    Y(0.676)   6
                 Evans          2003    Germany    Caucasians    CCS      CAD        HB         114/629      72/337     35/245     7/47      179/919      49/339    Y(0.789)   7
                 Harada         2003     Japan       Asian       CCS      CAD        HB         273/137      73/31      139/73     61/33     285/135     261/139    Y(0.440)   6
                  Wang          2004     China       Asian       CCS      CAD        PB         222/278      79/76      94/125     49/77     252/277     192/279    Y(0.093)   7
                  Zhao          2004     China       Asian       CCS      CAD        PB         236/251      96/80     111/123     29/48     303/283     169/219    Y(0.953)   8
                 Wang-a         2004     China       Asian       CCS      IS         PB          58/60       23/21      27/34       8/5       73/76       43/44     Y(0.088)   7
                 Wang-b         2004     China       Asian       CCS      IS         PB          58/60       19/14      35/36      4/10       73/64       43/56     Y(0.112)   7
                  Xiao          2004     China       Asian       CCS      IS         PB         379/351     149/112    172/172     58/67     470/396     288/306    Y(0.947)   8
                  Woll          2005      USA      Caucasians    CCS      CAD        PB         838/257     450/115    327/112     61/30     1227/342    449/172    Y(0.732)   6
                  Cui           2005     China       Asian       CCS      IS         PB          96/90       15/21      35/45      46/24      65/87       127/93    Y(0.992)   7
                Whiting         2005      USA        Mixed       CS       CAD        HB        2468/834     1298/449   975/318    195/67    3571/1216    1365/452   Y(0.313)   6
                  Sun           2005     China       Asian       CCS      CAD        PB         224/248      105/62     85/129     34/57     295/253     153/243    Y(0.521)   8
                   Li           2005     China       Asian       CCS      CAD        PB         264/278      104/83    116/132     44/63     324/298     204/258    Y(0.449)   7
                 Chang          2005     China       Asian       CCS      CAD        PB         178/83       66/17      75/22      37/44      207/56     149/110    N(0.000)   7
                  Wang          2006     China       Asian       CCS      CAD        PB         396/417     158/124    174/198     64/95     490/446     302/388    Y(0.350)  
                  Wang          2006     China       Asian       CCS      CAD        HB         150/139      61/47      69/53      20/39     191/147     109/131    N(0.006)   6
                  Wang          2006     China       Asian       CCS      CAD        PB         234/198      108/67    105/101     21/30     321/235     147/161    Y(0.422)   8
                  Cha           2006     China       Asian       CCS      CAD        PB         112/108      47/34      53/52      12/22     147/120      77/96     Y(0.795)   7
                   Wu           2006     China       Asian       CCS      CAD        PB          67/20        26/2       30/7      11/11      82/11       52/29     Y(0.585)   6
                 Martín         2006     Spain     Caucasians    CS       MI         HB         100/100      48/49      42/40      10/11     138/138      62/62     Y(0.516)   6
             Andrikovics-a      2006    Hungary    Caucasians    CCS      IS         PB         244/193      131/97     84/73      29/23     346/267     142/119    Y(0.116)   7
             Andrikovics-b      2006    Hungary    Caucasians    CCS      CAD        PB         150/193      84/97      55/73      11/23     223/267      77/119    Y(0.116)   7
                   Yu           2008     China       Asian       CCS      MI         PB          49/72       29/24      18/35      2/13       76/83       22/61     Y(0.969)   7
                 Zhang          2008     China       Asian       CCS      IS         PB         177/234      43/40      87/129     47/65     173/209     181/259    Y(0.078)   7
                  Wang          2008     China       Asian       CCS      CAD        HB         111/75       30/17      54/41      27/17      114/75      108/75    Y(0.419)   6
                 Zhang          2008     China       Asian       CCS      MI         PB         162/186      71/49      65/93      26/44     207/191     117/181    Y(0.992)   8
               Balcerzyk        2008    Poland     Caucasians    CCS      CAD        PB         178/180      90/91      68/78      20/11     248/260     108/100    Y(0.283)   6
             Frikke-Schmidt     2008    Denmark    Caucasians    CS       CAD        PB        1107/7858    603/4260   429/3032   75/566    1635/11552   579/4164   Y(0.405)   7
           Porchay-Baldérelli   2009    France     Caucasians    CS       CAD        HB        223/2906     106/1491   102/1183   15/232     314/4165    132/1647   Y(0.901)   6
                   Li           2009     China       Asian       CCS      CAD        PB         365/246      140/92    170/116     55/38     450/300     280/192    Y(0.886)   8
                  Shi           2009     China       Asian       CCS      CAD        HB         132/157      49/53      60/66      23/38     158/172     106/142    Y(0.058)   7
                 Doosti         2009     Iran        Asian       CCS      CAD        HB         207/94       71/17      77/38      59/39      219/72     195/116    Y(0.161)   6
                  Guo           2010     China       Asian       CCS      CAD        PB          71/83       30/29      37/38      4/16       97/96       45/70     Y(0.576)   7
                   Xu           2011     China       Asian       CCS      CAD        PB         246/109      95/31      128/53     23/25     318/115     174/103    Y(0.798)   8
                  Yuan          2011     China       Asian       CCS      CAD        PB          60/55       22/16      28/21      10/18      72/53       48/57     Y(0.081)   7
                   Yi           2011     China       Asian       CCS      IS         PB         240/240      36/45      97/109    107/86     169/199     311/281    Y(0.319)   7
                  Xue           2012     China       Asian       CCS    CAA, IS      PB         182/229      70/62      91/118     21/49     231/242     133/216    Y(0.608)   8
                  Wang          2012     China       Asian       CCS      CAD        PB         141/109      63/31      63/53      15/25     189/115      93/103    Y(0.798)   7
                   Li           2012     China       Asian       CCS      MI         PB         150/100      52/30      74/48      24/22     178/108      122/92    Y(0.735)   7
                  Xia           2012     China       Asian       CCS      CAD        HB         227/162      96/51      107/78     24/33     299/180     155/144    Y(0.750)   6
  M883I                                                                                                       M/M        M/I        I/I         M           I                 
                 Tan-a          2003   Singapore     Asian       CCS      CAD        PB         364/250      168/97    169/134     27/19     505/328     223/172    N(0.003)   7
                 Tan-b          2003   Singapore     Asian       CCS      CAD        PB         100/167      26/22      45/87      29/58      97/131     103/203    Y(0.231)   7
                 Tan-c          2003   Singapore     Asian       CCS      CAD        PB         152/223       6/3       20/34     126/186     32/40      272/406    Y(0.322)   7
                   Li           2005     China       Asian       CCS      CAD        PB         264/278     233/230     31/48       0/0      497/508      31/48     Y(0.115)   7
                  Sun           2005     China       Asian       CCS      CAD        PB         224/248     119/127     91/97      14/24     329/351     119/145    Y(0.389)   8
             Andrikovics-a      2006    Hungary    Caucasians    CCS      IS         PB         244/105      176/80     61/24       7/1      413/184      75/26     Y(0.583)   7
             Andrikovics-b      2006    Hungary    Caucasians    CCS      CAD        PB         150/105      117/80     29/24       4/1      263/184      37/26     Y(0.583)   7
                  Guo           2007     China       Asian       CCS      CAD        PB         112/108      54/51      50/43      8/14      158/145      66/71     Y(0.309)   7
                  Tsai          2007     China       Asian       CCS      CAD        PB         205/201     124/103     65/84      16/14     313/290      97/112    Y(0.574)   7
                 Jensen         2007      USA      Caucasians    CS       CAD        PB         243/482     187/352     51/120     5/10      425/824      61/140    Y(0.951)   7
           Porchay-Baldérelli   2009    France     Caucasians    CS       CAD        HB        223/2906     165/2057    52/782     6/67      382/4896     64/916    Y(0.469)   6
                 Zhang          2010     China       Asian       CCS      CAD        HB         289/171      201/94     83/73       5/4      485/261      93/81     N(0.018)   6
                  Mao           2011     China       Asian       CCS      CAD        PB         357/160      140/55     150/73     67/32     430/183     284/137    Y(0.388)   6
                  Liu           2011     China       Asian       CCS      IS         PB         90/100       51/68      31/28       8/4      133/164      47/36     Y(0.607)   7
                                                                                                              M/M      M/I+I/I                                                
                 Martín         2006     Spain     Caucasians    CS       MI         HB         100/100      69/80      31/20                                          --      6
             Frikke-Schmidt     2008    Denmark    Caucasians    CS       CAD        PB        1107/7858    827/6107   280/1751                                        --      7

CCS: case-control study, CS: cohort study, PB: population-based, HB: hospital-based, HWE: Hardy-Weinberg equilibrium, Y: yes, N: no, CAD: coronary artery disease, CAA: carotid artery atherosclerosis, IS: ischemic stroke, MI: myocardial infarction,
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###### Meta-analyses of ABCA1 R219K and M883I polymorphisms and risk of AS in each subgroup.
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                                                                    Allelic model       Additive model    Recessive model     Dominant model                                                   
  ----------------------------------------------- ------------- ---------------------- ---------------- -------------------- ---------------- ------------------- -------- ------------------- --------
  Overall analysis                                                                                                                                                                             
  R219K                                            12551/19548    0.77\[0.71,0.84\]         \<0.01       0.60\[0.51,0.71\]        \<0.01       0.69\[0.60,0.80\]   \<0.01   0.74\[0.66,0.83\]   \<0.01
  M883I                                            4224/13462     0.85\[0.77,0.95\]         \<0.01       0.79 \[0.61,1.01\]        0.06        0.92\[0.74,1.13\]    0.42    0.86\[0.72,1.02\]    0.08
  Subgroup analysis based on ethnicity                                                                                                                                                         
  R219K (C)                                        4616/13845     0.91\[0.80,1.04\]          0.16        0.83\[0.65,1.06\]         0.14        0.87\[0.72,1.05\]    0.14    0.90\[0.76,1.07\]    0.23
  R219K (A)                                         7935/5703     0.71\[0.64,0.79\]         \<0.01       0.52\[0.42,0.63\]        \<0.01       0.62\[0.52,0.75\]   \<0.01   0.66\[0.59,0.74\]   \<0.01
  M883I (C)                                        2067/11556     0.94\[0.78,1.12\]          0.48        1.24\[0.67,2.29\]         0.50        1.29\[0.70,2.38\]    0.41    1.05\[0.86,1.28\]    0.66
  M883I (A)                                         2157/1906     0.82\[0.72,0.93\]         \<0.01       0.72\[0.54,0.95\]         0.02        0.88\[0.70,1.09\]    0.25    0.75\[0.61,0.91\]   \<0.01
  Subgroup analysis based on type of diseases                                                                                                                                                  
  R219K (CAD)                                      11117/18091    0.74\[0.67,0.82\]         \<0.01       0.56\[0.47,0.67\]        \<0.01       0.64\[0.55,0.74\]   \<0.01   0.72\[0.64,0.82\]   \<0.01
  R219K (IS)                                        1434/1457     0.94\[0.75,1.17\]          0.58        0.86\[0.55,1.35\]         0.51        1.00\[0.69,1.45\]    1.00    0.82\[0.65,1.02\]    0.08
  M883I (CAD)                                      3890/13257     0.82\[0.74,0.90\]         \<0.01       0.73\[0.57,0.94\]         0.01        0.88\[0.71,1.09\]    0.24    0.81\[0.68,0.97\]    0.02
  M883I (IS)                                         334/205      1.43\[1.02,2.02\]          0.04        2.79\[0.95,8.21\]         0.06        2.51\[0.86,7.29\]    0.09    1.40\[0.94,2.07\]    0.10
  Subgroup analysis based on source of controls                                                                                                                                                
  R219K (PB)                                       7898/13799     0.76\[0.67,0.85\]         \<0.01       0.58\[0.47,0.72\]        \<0.01       0.68\[0.56,0.82\]   \<0.01   0.72\[0.62,0.83\]   \<0.01
  R219K (HB)                                        4653/5749     0.81\[0.71,0.92\]         \<0.01       0.65\[0.51,0.82\]        \<0.01       0.72\[0.59,0.87\]   \<0.01   0.80\[0.68,0.94\]   \<0.01
  M883I (PB)                                       3612/10285     0.87\[0.78,0.97\]          0.01        0.77\[0.58,1.04\]         0.09        0.91\[0.73,1.13\]    0.39    0.86\[0.72,1.04\]    0.11
  M883I (HB)                                        612/3177     0.75\[0.52,1.08\]^a^        0.13        0.93\[0.45,1.90\]         0.84        1.02\[0.50,2.09\]    0.95    0.88\[0.51,1.55\]    0.67
  Subgroup analysis based on study type                                                                                                                                                        
  R219K (CS)                                       4330/12056     0.97\[0.88,1.07\]          0.55        0.91\[0.75,1.10\]         0.32        0.91\[0.76,1.07\]    0.25    0.99\[0.87,1.12\]    0.84
  R219K (CCS)                                       8221/7492     0.74\[0.67,0.82\]         \<0.01       0.57\[0.47,0.68\]        \<0.01       0.67\[0.57,0.78\]   \<0.01   0.70\[0.62,0.79\]   \<0.01
  M883I (CS)                                       1673/11346     0.87\[0.71,1.08\]          0.21        1.05\[0.54,2.04\]         0.89        1.10\[0.56,2.14\]    0.78    1.04\[0.80,1.36\]    0.77
  M883I (CCS)                                       2551/2116     0.85\[0.75,0.97\]          0.01        0.75\[0.56,1.02\]         0.06        0.90\[0.72,1.12\]    0.34    0.79\[0.65,0.95\]    0.01
  Sensitivity analysis                                                                                                                                                                         
  R219K (BS)                                       7061/14128     0.76\[0.68,0.85\]         \<0.01       0.60\[0.49,0.73\]        \<0.01       0.69\[0.58,0.82\]   \<0.01   0.72\[0.62,0.83\]   \<0.01
  R219K (BH)                                       12223/19326    0.79\[0.72,0.86\]         \<0.01       0.62\[0.53,0.74\]        \<0.01       0.73\[0.64,0.83\]   \<0.01   0.75\[0.67,0.84\]   \<0.01
  R219K (BT)                                       11647/18669    0.78\[0.71,0.85\]         \<0.01       0.60\[0.51,0.71\]        \<0.01       0.70\[0.61,0.80\]   \<0.01   0.74\[0.66,0.83\]   \<0.01
  M883I (BS)                                       3255/10125     0.87\[0.77,0.99\]          0.03        0.77\[0.54,1.10\]         0.16        0.90\[0.71,1.16\]    0.42    0.87\[0.71,1.05\]    0.15
  M883I (BH)                                       3571/13041     0.88\[0.79,0.98\]          0.02        0.80\[0.58,1.10\]         0.17        0.92\[0.73,1.15\]    0.44    0.84\[0.71,0.98\]    0.03
  M883I (BT)                                       3870/13084     0.84\[0.76,0.92\]         \<0.01       0.75\[0.58,0.95\]         0.02        0.89\[0.72,1.10\]    0.29    0.85\[0.71,1.01\]    0.07

A: Asians, C: Caucasians, PB: population-based, HB: hospital-based.

CS: cohort study, CCS: case-control study.

BS: based on score (Studies with score ≤6 were excluded).

BH: based on HWE (Studies without HWE were excluded).

BT: based on article type (Master theses were excluded).

CAD: coronary artery disease, IS: ischemic stroke. SS: sample size.

Quantitative Synthesis {#s3b}
----------------------

For the ABCA1 R219K polymorphism, 42 studies were combined. The overall results showed evidence of significant association between the ABCA1 R219K polymorphism and the susceptibility to AS, suggesting that the ABCA1 R219K polymorphism was a protective role for AS (for K allele vs. R allele: OR = 0.77, 95% CI = 0.71--0.84, *P*\<0.01; for K/K vs. R/R: OR = 0.60, 95% CI = 0.51--0.71, *P*\<0.01; for K/K vs. R/K+R/R: OR = 0.69, 95% CI = 0.60--0.80, *P*\<0.01; for K/K+R/K vs. R/R: OR = 0.74, 95% CI = 0.66--0.83, *P*\<0.01). In addition, significant associations were also found between this variant and the susceptibility to AS in the Asians group (for K allele vs. R allele: OR = 0.71, 95% CI = 0.64--0.79, *P*\<0.01; for K/K vs. R/R: OR = 0.52, 95% CI = 0.42--0.63, *P*\<0.01; for K/K vs. R/K+R/R: OR = 0.62, 95% CI = 0.52--0.75, *P*\<0.01; for K/K+R/K vs. R/R: OR = 0.66, 95% CI = 0.59--0.74, *P*\<0.01), CAD group (for K allele vs. R allele: OR = 0.74, 95% CI = 0.67--0.82, *P*\<0.01; for K/K vs. R/R: OR = 0.56, 95% CI = 0.47--0.67, *P*\<0.01; for K/K vs. R/K+R/R: OR = 0.64, 95% CI = 0.55--0.74, *P*\<0.01; for K/K+R/K vs. R/R: OR = 0.72, 95% CI = 0.64--0.82, *P*\<0.01), population-based group (for K allele vs. R allele: OR = 0.76, 95% CI = 0.67--0.85, *P*\<0.01; for K/K vs. R/R: OR = 0.58, 95% CI = 0.47--0.72, *P*\<0.01; for K/K vs. R/K+R/R: OR = 0.68, 95% CI = 0.56--0.82, *P*\<0.01; for K/K+R/K vs. R/R: OR = 0.72, 95% CI = 0.62--0.83, *P*\<0.01), hospital-based group (for K allele vs. R allele: OR = 0.81, 95% CI = 0.71--0.92, *P*\<0.01; for K/K vs. R/R: OR = 0.65, 95% CI = 0.51--0.82, *P*\<0.01; for K/K vs. R/K+R/R: OR = 0.72, 95% CI = 0.59--0.87, *P*\<0.01; for K/K+R/K vs. R/R: OR = 0.80, 95% CI = 0.68--0.94, *P*\<0.01) and the subgroup of case-control study (for K allele vs. R allele: OR = 0.74, 95% CI = 0.67--0.82, *P*\<0.01; for K/K vs. R/R: OR = 0.57, 95% CI = 0.47--0.68, *P*\<0.01; for K/K vs. R/K+R/R: OR = 0.67, 95% CI = 0.57--0.78, *P*\<0.01; for K/K+R/K vs. R/R: OR = 0.70, 95% CI = 0.62--0.79, *P*\<0.01), respectively. The main results of meta-analysis were shown in [Table 2](#pone-0086480-t002){ref-type="table"}, [Fig. 2](#pone-0086480-g002){ref-type="fig"}, [Fig. S1](#pone.0086480.s001){ref-type="supplementary-material"}, [Fig. S2](#pone.0086480.s002){ref-type="supplementary-material"} and [Fig. S3](#pone.0086480.s003){ref-type="supplementary-material"}.

![Forest plot for ABCA1 R219K polymorphism and AS risk in the allelic model (K allele vs. R allele).](pone.0086480.g002){#pone-0086480-g002}

For the ABCA1 M883I polymorphism, 16 studies were combined. When all 16 studies were pooled into the meta-analysis, there was significant association between the ABCA1 M883I polymorphism and the susceptibility to AS in the allelic model (for I allele vs. M allele: OR = 0.85, 95% CI = 0.77--0.95, *P*\<0.01). However, no obvious evidence of association was found in the additive model (for I/I vs. M/M: OR = 0.79, 95% CI = 0.61--1.01, *P* = 0.06), recessive model (for I/I vs. M/I+M/M: OR = 0.92, 95% CI = 0.74--1.13, *P* = 0.42) and dominant model (for I/I+M/I vs. M/M: OR = 0.86, 95% CI = 0.72--1.02, *P* = 0.08). In the subgroup analyses, significant associations were found between this variant and the susceptibility to AS in the Asians group (for I allele vs. M allele: OR = 0.82, 95% CI = 0.72--0.93, *P*\<0.01; for I/I vs. M/M: OR = 0.72, 95% CI = 0.54--0.95, *P* = 0.02; for I/I+M/I vs. M/M: OR = 0.75, 95% CI = 0.61--0.91, *P*\<0.01), CAD group (for I allele vs. M allele: OR = 0.82, 95% CI = 0.74--0.90, *P*\<0.01; for I/I vs. M/M: OR = 0.73, 95% CI = 0.57--0.94, *P* = 0.01; for I/I+M/I vs. M/M: OR = 0.81, 95% CI = 0.68--0.97, *P = *0.02), IS group (for I allele vs. M allele: OR = 1.43, 95% CI = 1.02--2.02, *P = *0.04), population-based group (for I allele vs. M allele: OR = 0.87, 95% CI = 0.78--0.97, *P*\<0.01) and the subgroup of case-control study (for I allele vs. M allele: OR = 0.85, 95% CI = 0.75--0.97, *P = *0.01; for I/I+M/I vs. M/M: OR = 0.79, 95% CI = 0.65--0.95, *P = *0.01), respectively. The main results of meta-analysis were shown in [Table 2](#pone-0086480-t002){ref-type="table"}, [Fig. 3](#pone-0086480-g003){ref-type="fig"}, [Fig. S4](#pone.0086480.s004){ref-type="supplementary-material"}, [Fig. S5](#pone.0086480.s005){ref-type="supplementary-material"}, and [Fig. S6](#pone.0086480.s006){ref-type="supplementary-material"}.

![Forest plot for ABCA1 M883I polymorphism and AS risk in the allelic model (I allele vs. M allele).](pone.0086480.g003){#pone-0086480-g003}

Sensitivity Analysis {#s3c}
--------------------

Sensitivity analyses were conducted to determine whether modification of the inclusion criteria of the meta-analysis affected the final results. The included studies were limited to those conforming to HWE or the high quality studies (NOS score ≥7). In addition, we also performed sensitivity analysis by removing the master thesis. Overall, the corresponding pooled ORs were not materially altered, either for the ABCA1 R219K polymorphism or for M883I polymorphism. This suggested that the overall results of this meta-analysis were statistically robust. The main results of sensitivity analyses were shown in [Table 2](#pone-0086480-t002){ref-type="table"}.

Heterogeneity Analysis {#s3d}
----------------------

For the ABCA1 R219K polymorphism, significant heterogeneity existed in the overall comparisons (for allelic model: *P~Q~*\<0.01, I^2^ = 77.4%; for additive model: *P~Q~*\<0.01, I^2^ = 67.9%; for recessive model: *P~Q~*\<0.01, I^2^ = 64.2%; for dominant model: *P~Q~*\<0.01, I^2^ = 69.7%). For the ABCA1 M883I polymorphism, significant heterogeneity existed in the dominant model (for *P~Q~*\<0.01, I^2^ = 64.3%). In contrast, the allelic model, additive model and recessive model did not present significant heterogeneity (for allelic model: *P~Q~* = 0.24, I^2^ = 19.5%; additive model: *P~Q~* = 0.37, I^2^ = 7.9%; for recessive model: *P~Q~* = 0.75, I^2^ = 0%). To clarify the sources of heterogeneity, we conducted the meta-regression analysis.

For the ABCA1 R219K polymorphism, heterogeneity can be explained by the subtype of atherosclerotic diseases (allelic model: *P~T2~* = 0.013, additive model: *P~T2~* = 0.034, and recessive model: *P~T2~* = 0.017) and study type (dominant model: *P~T4~* = 0.037). According to the results of the meta-regression, we performed subgroup analyses based on the atherosclerotic diseases (CAD and IS) and study type (case-control and cohort study). Heterogeneity was distinctly reduced, although it was still significant in the allelic model (IS group: *P~Q~* = 0.0005, I^2^ = 71%; CAD group: *P~Q~*\<0.01, I^2^ = 79%), additive model (IS group: *P~Q~* = 0.001, I^2^ = 69%; CAD group: *P~Q~*\<0.01, I^2^ = 68%), recessive model (IS group: *P~Q~* = 0.0008, I^2^ = 70%; CAD group: *P~Q~*\<0.01, I^2^ = 59%) and dominant model (CS group: *P~Q~* = 0.14, I^2^ = 42%; CCS group: *P~Q~*\<0.01, I^2^ = 66%). For the ABCA1 M883I polymorphism, we did not indentify the sources of heterogeneity by the meta-regression. The main results of meta-regression were shown in [Table S3](#pone.0086480.s009){ref-type="supplementary-material"} and [Table S4](#pone.0086480.s010){ref-type="supplementary-material"}.

Publication Bias {#s3e}
----------------

Begg's funnel plot and Egger's regression test were performed to assess potential publication bias. For the ABCA1 R219K polymorphism, visual inspection of the funnel plot ([Fig. 4:](#pone-0086480-g004){ref-type="fig"} K allele vs. R allele) displays asymmetrical distribution of OR estimations, suggesting significant publication bias. In addition, the results of Egger's regression test also provided evidence for publication bias (*P*\<0.01 for allelic model, *P*\<0.01 for additive model, *P*\<0.01 for recessive model, and *P*\<0.01 for dominant model). For the ABCA1 M883I polymorphism, no obvious asymmetry was observed in any genetic model according to the visual assessment of funnel plot ([Fig. 4:](#pone-0086480-g004){ref-type="fig"} I allele vs. M allele). Moreover, the results of Egger's regression test did not provide any statistical evidence for publication bias (*P* = 0.34 for allelic model, *P* = 0.24 for additive model, *P* = 0.10 for recessive model, and *P* = 0.09 for dominant model). In addition to the above analyses, we also calculated the Nfs (for the ABCA1 R219K polymorphism, Nfs = 133 for allelic model, Nfs = 146 for additive model, Nfs = 75 for recessive model, and Nfs = 49 for dominant model; for the ABCA1 M883I polymorphism, Nfs = 50 for allelic model), which reflected the minimum number of non-significant studies that would lead to the P-value to non-significant (*P*\>0.05).

![Funnel plots for ABCA1 R219K and M883I polymorphisms and AS risk.\
K allele vs. R allele for ABCA1 R219K polymorphism. I allele vs. M allele for ABCA1 M883I polymorphism.](pone.0086480.g004){#pone-0086480-g004}

Discussion {#s4}
==========

To the best of our knowledge, this is the first comprehensive meta-analysis to date investigating the associations between the ABCA1 R219K and M883I polymorphisms and AS risk. Forty-two studies investigating the association between the ABCA1 R219K polymorphism and AS risk were combined [@pone.0086480-Clee1]--[@pone.0086480-Xia1], and 16 studies investigating the association between the ABCA1 M883I polymorphism and AS risk were combined [@pone.0086480-Sun1], [@pone.0086480-Li1], [@pone.0086480-Martn1], [@pone.0086480-Andrikovics1], [@pone.0086480-FrikkeSchmidt1], [@pone.0086480-PorchayBaldrelli1], [@pone.0086480-Tan1]--[@pone.0086480-Liu1]. According to the GRADE approach, the quality of the evidence was very low in the ABCA1 R219K polymorphism. For the ABCA1 M883I polymorphism, GRADE suggested that the quality of the evidence was moderate, except for the dominant model (Low). The overall findings showed that the ABCA1 R219K and M883I polymorphisms may exert an reduced risk effect on AS. For the ABCA1 R219K polymorphism, the risk of developing AS in R allele carriers was 1.30-fold higher than those without R allele. Furthermore, the individuals with K/K genotype had a significantly lower risk for developing AS (for OR = 0.60 in additive model and OR = 0.69 in recessive model) compared to those with R/K genotype and R/R genotype. As for the ABCA1 M883I polymorphism, the combined evidence showed that the individuals with I allele had a significantly lower risk for developing AS (for OR = 0.85 in allelic model) compared to those without I allele. Therefore, it is reasonable to assume that the ABCA1 R219K K allele and M883I I allele are the protective factors for the development of AS.

To make a more comprehensive analysis, subgroup analyses were performed based on ethnicity, atherosclerotic disease, source of controls and study type. For the ABCA1 R219K polymorphism, significant associations were found between this variant and the susceptibility to AS in the Asians group, CAD group, population-based group, hospital-based group and the subgroup of case-control study, respectively. These results further strengthened the conclusion that the ABCA1 R219K K allele was a protective factor for AS. However, we did not find significant association between this variant and AS risk in Caucasians group, IS group and the subgroup of cohort study. For the ABCA1 M883I polymorphism, significant associations were found between this variant and the susceptibility to AS in the Asians group, CAD group, IS group, population-based group and the subgroup of case-control study, respectively. Similarly, no significant association was found between the ABCA1 M883I polymorphism and AS risk in Caucasians group and the subgroup of cohort study. Moreover, we also did not find significant association between this variant and AS risk in hospital-based group. One potential explanation is that controls in the hospital-based group may not truly represent the underlying source populations because the ABCA1 M883I polymorphism has been reported to be associated with various diseases. For instance, in 2004, Katzov et al. found that the ABCA1 polymorphism were involved in the process of cholesterol metabolism of the brain and may affect the risk of Alzheimer's disease [@pone.0086480-Katzov1]. In 2007, Kitjaroentham et al. indicated that the presence of ABCA1 polymorphism could be a risk factor for overweight/obesity among Thai males [@pone.0086480-Kitjaroentham1]. However, there was a noteworthy result in the IS group which suggested the ABCA1 M883I polymorphism was associated with an increased AS risk. This finding was inconsistent with the overall results, which may affect the interpretation of the final results. Throughout the IS group, it should be noted that the sample size in this group was really small (334 IS cases and 205 controls), which could increase the probability of false positives or false negatives. Therefore, this result should be interpreted with caution.

In the subgroup analysis based on ethnicity, we only obtained the positive result in the Asians. For Caucasians, we did not find significant association between the ABCA1 R219K and M883I polymorphisms and AS risk. In fact, the minor allele frequencies (MAF) of ABCA1 R219K and M883I are low among utah residents with Northern and Western European ancestry (CEU) (MAF = 0.210 and 0.133 in HapMap CEU) [@pone.0086480-International1]. However, the ABCA1 R219K and M883I polymorphisms are common among Han Chinese in Beijing, China (CHB) and Japanese in Tokyo, Japan (JPT) (MAF = 0.453/0.434 and 0.255/0.438, respectively) [@pone.0086480-International1]. Compared with the overall results, the inconsistent results of Caucasians group may be partly due to genetic diversity among ethnicities. Moreover, as AS is a multifactorial disease, in addition to genetic factors, environmental factors also play an important role in AS etiology. Thus, this discrepancy may also be caused by varied geographic distribution, linked to climate, diet, lifestyle and economic status.

Considering the studies without HWE or with low NOS score may influence the overall results, subsequent sensitivity analyses restricted to the studies with HWE or high NOS score were performed. Although the corresponding pooled OR was materially altered in the dominant model (OR = 0.84, 95% CI = 0.71--0.98, *P* = 0.03) of the ABCA1 M883I polymorphism (Based on HWE), this result further strengthened the conclusion that the ABCA1 M883I polymorphism was a protective factor for AS. As for the ABCA1 R219K polymorphism, the corresponding pooled ORs were not materially altered in all comparisons. These results suggested that the studies without HWE should be considered as a factor influencing the overall results.

Significant heterogeneity existed in the present meta-analysis, either for the ABCA1 R219K polymorphism or for the ABCA1 M883I polymorphism. Heterogeneity should not be ignored and should be carefully factored in the interpretation of the finally results [@pone.0086480-Ioannidis1]. For the ABCA1 R219K polymorphism, the heterogeneity can be explained by the subtype of atherosclerotic diseases (CAD and IS) and study type (case-control and cohort study). For the ABCA1 M883I polymorphism, we did not indentify the sources of heterogeneity by the meta-regression. Common reasons of heterogeneity may include diversity in design, measurement errors, difference of ethnicity, or the interaction with other risk factors. Due to lack of original data, we did not perform further meta-regression analysis by the other factors.

For better interpreting the results, some limitations of this meta-analysis should be acknowledged. Firstly, there was significant heterogeneity in this meta-analysis. Heterogeneity may affect the precision of overall results, despite the use of appropriate meta-analytic techniques with random-effects model. Secondly, in the subgroup analyses, the sample sizes in some subgroup, such as the IS group and the hospital-based group of the ABCA1 M883I polymorphism, were relatively small, not having enough statistical power to explore the real association. Thirdly, publication bias was a potential problem that may bias the present results. Due to language restriction, some inevitable publication bias may exist in the present meta-analysis. Moreover, AS is a complex disease, involving potential interactions among gene-gene and gene-environment. A single gene polymorphism is insufficient to provide the complete explanation of genetic risk for AS. However, many eligible studies included in this meta-analysis did not consider the environmental factors.

In conclusion, the present meta-analysis suggested that the ABCA1 R219K and M883I polymorphisms were associated with the susceptibility to AS, especially in Asians. However, the result should be interpreted with caution because of its limitations. Further studies with large sample size, especially with the consideration of gene-gene and gene-environment interactions, will be needed to confirm our findings.
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